Germany to Soften Cannabis Insurance Reforms as Exilby Row Grows

Germany signals a softer line on cannabis insurance reform

Germany is preparing to water down planned cannabis insurance reforms, according to a Business of Cannabis report dated Oct. 6, 2026. The same report ties the shift to an escalating lobbying row involving Exilby.

That's the verified picture so far. The report's headline is the only detail CannIntel could confirm, and we aren't going to pad it.

What the report does and doesn't establish

The available signal confirms a direction of travel, not the text of any amendment. It doesn't say which provisions would be softened, which ministry is driving the change, or what Exilby's role is.

We haven't seen a draft bill, a Bundestag document or a ministry statement. Until one surfaces, treat specifics circulating on social media as unverified. Not yet.

Why the Exilby dispute matters beyond one name

A public lobbying fight over an insurance rule suggests the commercial stakes are large enough to draw scrutiny. Reimbursement design decides which products, prescribers and supply channels get paid.

Lobbying rows also tend to slow legislation, because a ministry that looks responsive to one commercial interest invites challenge from every other. That's the structural risk here, whatever the facts of this particular dispute turn out to be.

A softer reimbursement rule doesn't remove the fight over who pays for German medical cannabis. It moves the fight to implementation, where it's harder to see.

How German reimbursement works today

Since 2017, statutory health insurers have covered cannabis-based medicines for seriously ill patients under German medical cannabis law and Section 31(6) of the social code (SGB V), with first prescriptions requiring insurer approval. Insurers can only refuse with justification.

Germany's 2024 Cannabis Act removed medical cannabis from the Narcotics Act, so it now moves on ordinary prescriptions. The insurer approval step for first-time therapy is the pressure point any "insurance reform" would most likely touch. We can't confirm that it does here.

The chemistry wrinkle: THCA, decarboxylation and what gets paid for

Any reimbursement rule tied to potency has to pick a metric, and THC and THCA aren't interchangeable. Raw flower is mostly THCA, which converts to active delta-9 THC when heat triggers decarboxylation.

The conversion isn't one-to-one. The molecular weight ratio puts the theoretical yield near 0.877 grams of THC per gram of THCA, and real-world vaporization or heating loses more. A rule pegged to labeled THC alone prices a different product than one pegged to total THC after conversion. That's the same delta-9-versus-total-THC fight hemp operators already know from the U.S., and German payers will face their own version of it.

What operators and patients should watch

The practical questions are approval friction, prescriber behavior and payment timing. A looser approval process would help patients on the margin and help importers whose volume depends on prescriptions.

Operators should track three things:

• Whether the first-prescription approval step changes
• Whether any potency or product-form limits are written into reimbursement
• Whether the lobbying dispute produces a formal inquiry or disclosure

Investors holding German import exposure should watch the same items. Delay is a cost too.

Enforcement and timing remain unsettled

No effective date, vote or implementation timeline appears in the signal. Insurers have historically varied in how aggressively they apply approval rules, so expect enforcement to vary again regardless of what a softened text says.

For full background, see the CannIntel topic hub on Germany Medical Cannabis Reform. The next signal to watch is a published draft or ministry statement that names the provisions being changed; until one appears, the scope of any softening stays unsettled, and so does the timing.